A major new review of 262 clinical trials has ranked 19 obesity medicines by weight loss and cardiovascular benefit. The results reveal a striking gap between which drug slims you fastest and which drug may keep you alive longer. Here is what UK patients need to understand.
A landmark systematic review published in the BMJ in July 2026 compared 19 obesity medicines across 262 clinical trials. According to the BMJ, tirzepatide and CagriSema produced the largest estimated weight reductions. However, injectable semaglutide currently holds the strongest evidence for reducing deaths, heart attacks and kidney disease. The findings are reshaping how clinicians and patients should think about choosing an obesity medicine.
What Happened?
According to the BMJ, researchers analysed 262 trials covering 19 different obesity medicines. The review ranked medicines by two separate measures. The first was how much weight patients lost. The second was how much evidence exists for reducing serious health outcomes.
According to the BMJ, tirzepatide produced the largest estimated weight reduction among currently available treatments. CagriSema, a newer combination medicine, also produced very large estimated weight reductions in the review. Both outperformed injectable semaglutide on weight loss alone.
However, according to the BMJ, injectable semaglutide currently has the strongest evidence base for reducing cardiovascular deaths, heart attacks and kidney disease progression. This is because semaglutide has been studied in large, long-term outcomes trials over many years. Newer medicines simply have not yet accumulated the same volume of long-term safety and outcomes data.
According to the BMJ, the evidence for retatrutide and other emerging treatments remains low certainty at this stage. Retatrutide is not yet widely available in the UK, though interest is growing. You can read more about its expected arrival in our Retatrutide UK Guide.
Why This Story Matters
This review matters because public conversations about obesity medicines are almost entirely focused on weight loss numbers. Social media, newspapers and private clinic marketing frequently lead with how much weight a treatment can produce. The BMJ review asks a different and more important question: which medicine has the strongest evidence for keeping patients healthier for longer?
UK patients choosing between obesity medicines privately often compare cost and expected weight loss. Very few conversations focus on cardiovascular outcomes data or evidence certainty. According to the BMJ, the medicine producing the most weight loss may not always be the medicine with the strongest safety and outcomes evidence.
This matters particularly for women in midlife, who face elevated cardiovascular risk alongside increased pressure to manage weight. A treatment that produces impressive weight loss but lacks long-term outcomes evidence may not serve every patient equally well. The gap between weight loss headlines and outcomes evidence is a genuine and underreported issue in UK patient decision-making.
For a broader overview of how weight loss injections work and what to expect, our Weight Loss Jabs Guide is a useful starting point.
What This Means For UK Patients
The BMJ review is a reminder that choosing an obesity medicine involves more than comparing weight loss percentages. According to the BMJ, injectable semaglutide currently has the strongest evidence for reducing deaths, heart attacks and kidney disease. That matters enormously if you have existing cardiovascular risk, type 2 diabetes or kidney concerns.
Tirzepatide, available in the UK as Mounjaro, produces larger estimated weight reductions according to the BMJ. It is a very reasonable choice for many patients. But the evidence base for its long-term cardiovascular outcomes, while growing, is not yet as extensive as semaglutide’s. CagriSema is not yet widely available in the UK. Retatrutide remains at an early evidence stage.
A good UK prescriber should discuss your personal health history, not just your weight loss goal. If you are comparing private clinics and costs, our Mounjaro Price Comparison UK guide can help. Ask any prescriber directly about outcomes evidence, not just expected weight loss figures. Evidence quality is a legitimate and important question for patients to raise.
What Happens Next?
Long-term outcomes trials for tirzepatide are ongoing and results are expected in coming years. According to the BMJ, evidence for retatrutide and newer emerging treatments remains low certainty at this stage. That picture will change as more trial data accumulates. UK patients and clinicians should expect the evidence rankings to shift as newer medicines are studied over longer periods.
The MHRA will continue to review safety and efficacy data as it emerges for all licensed obesity medicines. Private clinics may use the weight loss findings from this BMJ review in their marketing. Patients should ask whether marketing claims refer to weight loss data or outcomes data. The two are very different things. Our Regulation and Policy section covers how obesity medicines are governed in the UK.
NHS access to newer obesity medicines remains limited and rationed by clinical criteria. The strongest outcomes evidence currently supporting injectable semaglutide may reinforce its position on NHS pathways for the foreseeable future.
Frequently Asked Questions
Which obesity medicine produces the most weight loss according to the BMJ review?
According to the BMJ, tirzepatide and CagriSema produced the largest estimated weight reductions across the 262 trials reviewed. CagriSema is not yet widely available in the UK.
Does the medicine with the most weight loss have the best overall evidence?
Not necessarily. According to the BMJ, injectable semaglutide currently has the strongest evidence for reducing deaths, heart attacks and kidney disease, despite producing smaller weight reductions than tirzepatide or CagriSema.
What does low certainty evidence mean for retatrutide and newer obesity medicines?
According to the BMJ, evidence for retatrutide and other emerging treatments remains low certainty. This means long-term outcomes data is limited. It does not mean the medicines are unsafe, but patients should understand that the evidence base is still developing.
Should UK patients choose their obesity medicine based on weight loss alone?
Independent analysis of the BMJ findings suggests that weight loss figures are only one part of a bigger picture. Patients with cardiovascular risk, kidney disease or type 2 diabetes should discuss outcomes evidence directly with their prescriber before choosing a treatment.
Is CagriSema available in the UK?
CagriSema is not yet widely available in the UK as of mid-2026. It produced some of the largest estimated weight reductions in the BMJ review, but UK patients cannot currently access it through standard private or NHS routes.
This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment.
Get the UK peptide medicine briefing in your inbox.
Free weekly. No spam. Unsubscribe any time.
This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment. Information correct at time of publication. The Peptide Brief updates articles when guidance changes.
